Clinical trials: Neoplasm Circulating Cells
Carcinoma, Non-small-cell Lung Cancer
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
- Conditions
- Carcinoma, Non-small-cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT02696525
- Where
- 3 sites in China
- Volunteers
- 145 people
- Sponsor
- Peking University People's Hospital
Cancer, Spinal Disease
Anderson Circulating Tumor Cell Burden (CTCB) Study
Phase 1 - Optimization Phase: Primary Objective: The primary objective of Phase 1 of this study is to determine the time point at which maximal Circulating Tumor Cell Burden (CTCB) occurs following standard vertebroplasty and…
- Conditions
- Cancer, Spinal Disease, Vertebral Compression Fractures
- Trial name
- NCT00819832
- Testing
- Kyphoplasty, Vertebroplasty, Cavity SpineWand
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Pulmonary Nodules, Solitary, Pulmonary Nodules, Multiple
Early Adjuvant Diagnosis of Pulmonary Nodules Based on CTC.
The goal of this observational clinical trial is to evaluate the value of circulating tumor cell detection in the early diagnosis of malignant pulmonary nodule.
- Trial name
- NCT06187935
- Where
- China
- Volunteers
- 172 people
- Sponsor
- China-Japan Friendship Hospital
Mycosis Fungoides, Lymphoma, Large B-cell, Diffuse
Cell-free Circulating DNA in Primary Cutaneous Lymphomas
To evaluate the possibility of detecting cell-free circulating tumoral DNA in potentially aggressive primary cutaneous lymphomas, the investigator opted to search a representative tumor sample mutation in the blood of these…
- Trial name
- MATULILA (NCT02883517)
- Testing
- Cytogenetic and molecular studies
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Bordeaux
Metastatic Colorectal Cancer, Circulating Tumor Cell
Circulating Tumor Cells in mCRC for Liver Resection
Resection of liver metastasis is potentially curative in patients with colorectal cancer bearing liver metastasis. However, early recurrence occurs in up to 30% in 3 months after liver resection.
- Trial name
- NCT03295591
- Testing
- Circulating tumor cell
- Where
- Hong Kong
- Volunteers
- 77 people
- Sponsor
- The University of Hong Kong
Primary Central Nervous System Lymphoma (PCNSL)
Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China
This project aims to establish and prospectively register a longitudinal, multimodal biobank for primary central nervous system lymphoma (PCNSL).
- Trial name
- CLIMB (NCT07842835)
- Testing
- High-dose methotrexate-based therapy, Bruton tyrosine kinase inhibitor-based therapy
- Where
- 3 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Xiaohui Ren
Circulating Tumor Cells
Culture of Circulating Tumor Cells Isolated From Cancer Patients With Metastatic Disease
The purpose of this study is to investigate the feasibility of using novel decellularized tissue matrices to isolate and culture circulating tumor cells (CTCs) collected from patients with metastatic solid tumor malignancies.
- Trial name
- NCT02781025
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer, Circulating Tumor Cell
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients
The goal of this observational study is to compare the number of CTCs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients.
- Conditions
- Prostate Cancer, Circulating Tumor Cell, Leukapheresis
- Trial name
- NCT06469710
- Testing
- leukapheresis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- RenJi Hospital
Rectal Cancer
Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer
Rectal cancer is one of the most common malignant tumors in the world. However, there's also no reliable and sensitive method to monitor diseases and evaluate therapy responses till now.
- Trial name
- NCT01671891
- Testing
- radiation therapy, capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fudan University
Melanoma, Circulating Tumor Cell
Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology
Several studies conducted over the past decade have shown that Circulating tumor cells (CTCs) can be used as a marker for predicting disease progression and survival in patients with early or metastatic cancer.
- Trial name
- EXPEVIVO-CTC (NCT03797053)
- Testing
- Biological sample
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Carcinoma, Hepatocellular, Neoplasm Circulating Cells
Circulating Tumor Cells for Hepatocellular Carcinoma
To explore the clinical value of circulating tumor cells (CTCs) measurement for Hepatocellular carcinoma (HCC) patients.
- Trial name
- CTCs for HCC (NCT01930383)
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Cancer, Breast Cancer
Analysis of Circulating Tumor Markers in Blood
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency…
- Conditions
- Cancer, Breast Cancer, Sarcoma, Lung Cancers
- Trial name
- ALCINA2 (NCT04025541)
- Testing
- Blood sampling, Blood sampling C3, Blood sampling C4/7/10/13
- Where
- 2 sites in France
- Volunteers
- 992 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Circulating Tumor Cells
Therapeutic Response Evaluation by CTC Expansion System
Among biomarkers, CTCs are a convenient, sensitive and biologically informative option. CTC detection could be considered a real-time "liquid biopsy" approach and contains several advantages such as minimally invasive, easy and…
- Trial name
- NCT04972461
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Taipei Medical University Hospital
Merkel Cell Carcinoma
Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma
The goal of this prospective observational study is to evaluate the presence of circulating tumoral cells in patients over 18 with a stage I-III resectable Merkel cell carcinoma after the initial therapeutic sequence of surgery…
- Trial name
- MERCCALIBI (NCT06448611)
- Testing
- Blood Test
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
Lung Neoplasms, Pulmonary Disease, Chronic Obstructive
Circulating Tumor Cells in Lung Cancer Screening
This trial is intended to evaluate the value of circulating tumor cells (CTC), in combination with unenhanced (without injection of contrast media) low dose (to limit the effective radiation dose below 1,5 mSv) chest computed…
- Trial name
- AIR (NCT02500693)
- Testing
- Isolation of circulating tumor cells (CTC) from veinous blood
- Where
- 20 sites in France
- Volunteers
- 683 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Multiple Myeloma
CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid-19)
The coronavirus (COVID-19) pandemic has brought severe challenges for myeloma patients. Myeloma patients are considered ultra-high risk for COVID-19 and fall into the strictest group for shielding.
- Trial name
- NCT04659252
- Testing
- n/a - samples collected along routine care samples only
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Cell Free DNA and Its Integrity Using ALU Sequences as a Biomarker for Diagnosis of Breast Cancer
Breast cancer (BC) is the most common cancer in women worldwide, and is the leading cause of death from cancer among women globally.
- Trial name
- NCT03474016
- Testing
- Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Assiut University
Colorectal Neoplasms Malignant, Minimal Residual Disease
Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III
This trial has been designed to prove the feasibility of using liquid biopsy detection of minimal residual disease (MRD) to guide the postsurgical clinical management of early colon cancer patients.
- Conditions
- Colorectal Neoplasms Malignant, Minimal Residual Disease, Circulating Tumor Cell
- Trial name
- NCT07821333
- Testing
- FOLFOXIRI, CAPOX
- Where
- 7 sites in Spain
- Volunteers
- 45 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Colorectal Cancer, Circulating Tumor Cell
Clinical Significance of Detecting CEA and CK20 mRNA-positive Cells in Colorectal Cancer Patients
To determine whether the presence of circulating/disseminated tumor cells (CTCs/DTCs) in the blood and bone marrow of colorectal cancer (CRC) patients with localized disease is a negative prognostic factor, and to find…
- Trial name
- NCT03337347
- Testing
- CTC/DTC count
- Where
- Czechia
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity.
- Trial name
- GOLD (NCT06828991)
- Testing
- Mosunetuzumab, ClonoSEQ
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Danielle Wallace